STAT+: Pharmalittle: FTC suit over Amgen spotlights ‘bundling’ deals with insurers; FDA staff says Pfizer RSV vaccine is effective
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
Category: Pharmalot
STAT+: FTC move to block the Amgen-Horizon deal highlights concerns over negotiations with insurers
In an unexpected move, the U.S. Federal Trade Commission on Tuesday filed a lawsuit to…
STAT+: Pharmalittle: FTC may sue to block Amgen deal for Horizon; Supreme Court declines Teva appeal on skinny labeling
Oh, what a beautiful morning! Pardon the cliché, but crystal clear blue skies and deliciously…
STAT+: U.S. Supreme Court declines to hear ‘skinny labeling’ case with implications for generic drug access
After months of anticipation, the U.S. Supreme Court declined to hear an appeal of a…
STAT+: Pharmalittle: FDA OKs new kind of drug to treat hot flashes; Alzheimer’s drug could cost Medicare up to $5 billion a year
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: U.S. Senate committee passes PBM bills; Pfizer CEO predicts pharma will sue over Medicare price negotiations
And so, another working week will soon draw to a close. Not a moment too…
STAT+: AbbVie sues a behind-the-scenes company for exploiting its patient assistance program
AbbVie has filed a lawsuit against a behind-the-scenes company that helps health plan sponsors take…
STAT+: Wyden decries ‘astonishingly low’ tax rates for pharma companies as he probes business maneuvers
Thanks to changes in tax law six years ago, several of the largest pharmaceutical companies…
STAT+: Pharmalittle: FDA panel recommends first OTC birth control pill; Senate hearing on insulin costs satisfies no one
Hello, everyone, and how are you today? We are doing just fine, thank you, as…
FDA panel votes in favor of the first-ever over-the-counter birth control pill
In a highly significant move, a panel of independent experts on Wednesday voted unanimously that…
STAT+: Pharmalittle: Gilead wins lawsuit against HHS over HIV pill patents; most Americans say abortion pill should remain on the market
Hello, everyone, and how are you this fine, sunny morning? The middle of the week…
STAT+: What FDA mandate? Sun Pharma halts shipments from a plant with a troubled history
In a fresh sign of quality-control problems in the Indian pharmaceutical industry, the U.S. Food…
STAT+: Gilead defeats federal government in closely watched battle over patents for HIV prevention pills
A U.S. court jury handed a major win to Gilead Sciences on Tuesday in a…
STAT+: Pharmalittle: Big pharma maps legal strategy against U.S. drug pricing reform; U.S. pharma layoffs continue to climb
Top of the morning to you, and a fine one it is. The sun is…
STAT+: Pharmalittle: FDA panel to review over-the-counter birth control pill; Alzheimer’s drugs may lead to haves and have-nots
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: Pfizer and Valneva delay application for Lyme vaccine; Moderna adjusts price for Covid-19 shot
And so, another working week will soon draw to a close. Not a moment too…
STAT+: NIH grant recipients often fail to disclose agency support in patent applications
The National Institutes of Health may be the largest public funder of biomedical research in…
STAT+: Scientific research will be threatened unless NIH overhauls systems for tracking non-human primates, report warns
A worsening shortage of non-human primates and an inadequate government response threatens to undermine biomedical…
STAT+: Pharmalittle: FDA OKs first RSV vaccine for older adults; Lilly Alzheimer’s data puts pressure on Medicare
Rise and shine, another busy day is on the way. We can tell by the…
STAT+: Pharmalittle: Lilly’s Alzheimer’s drug slowed cognitive decline; most EU countries back plan to push production of key drugs
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT+: Pharmalittle: Senate PBM reform bill delays effective date; Gilead and HHS square off in court over HIV patents
Good morning, everyone, and how are you today? Steely skies are hovering this morning over…
STAT+: A battle between Gilead and the U.S. government over patents on HIV prevention pills goes to trial
After years of sparring, the federal government and Gilead Sciences will square off in a…
STAT+: Most of Canada’s public research universities get bad grades for ensuring access to drugs they discover
Despite significant public funding, most of the 15 largest public research universities in Canada failed…
STAT+: Pharmalittle: More biotechs are betting on obesity; Pfizer RSV vaccine faces hurdles in low-income countries
Good morning, everyone, and nice to see you again after a week-long respite in which…
STAT+: Pharmalittle: Amgen ends two lupus programs; Illumina sequencers have security vulnerability
Hello and happy Friday, with STAT reporter Andrew Joseph here steering the ship in place…
STAT+: Covid-19 burnished pharma’s reputation among patient groups, but access to medicines is now an issue
In the wake of the Covid-19 pandemic, the pharmaceutical industry enjoyed something of an afterglow,…
STAT+: Pharmalittle: Lilly’s Mounjaro helped people lose 15.7% of body weight; Sanofi earnings boosted by Dupixent
Good morning everyone, from STAT reporter Andrew Joseph here filling in for Ed. Or, if…
.jpg)
STAT+: Pharmalittle: EU unveils sweeping pharma reforms; new eye drug helps Roche beat the street
Hello, everyone. Damian Garde here, filling in for Ed Silverman once more as the working…
STAT+: Pharmalittle: Novartis boosts its sales and profit outlook; Biogen trims its drug pipeline
Good morning, one and all. Damian Garde here, filling in for Ed Silverman on an…
.jpg)
STAT+: Maryland pushes first-of-its-kind bill to promote alternatives to animals in biomedical research
Amid a push to use fewer animals in medical research, Maryland is on the verge…
STAT+: Pharmalittle: Weight-loss drug makers lobby Congress for Medicare coverage; Europe braces for new pharma legislation
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: ‘A tug of war’: Europe braces for new legislation with far-reaching impacts on pharma and patients
After more than two years of planning, the European Commission on Wednesday will release long-awaited…
STAT+: Pharmalittle: Lilly expects Medicare to back down on Alzheimer’s drug coverage; key senators change insulin cap proposal
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: White House to tap cancer center chief to lead NIH; generic abortion pill maker sues FDA
Top of the morning to you. Gray skies are hovering over the Pharmalot campus right…
STAT+: STAT-Harris Poll: Most Americans are worried about RSV
A majority of Americans are concerned about the health threat posed by the respiratory syncytial…
STAT+: Pharmalittle: GSK manufacturing workers in the U.K. to strike in May; weight-loss drugs prompt strange dreams
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: Mark Cuban’s drug company creates a pharmacy network to challenge PBMs
In its latest bid to upend the pharmaceutical supply chain, the Mark Cuban Cost Plus…
STAT+: Pharmalittle: GSK will buy Bellus Health for $2 billion; FDA inspectors are leaving faster than they can be replaced
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Most large U.S. funders of clinical research have poor transparency policies, analysis finds
Amid ongoing concern over clinical trial transparency, a new analysis finds that only 37% of…
STAT+: Pharmalittle: Merck to acquire Prometheus Biosciences for $10.8 billion; mRNA cancer vaccine reduces melanoma relapse
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: Telehealth abortion providers are scrambling; Express Scripts launches new pricing plan amid PBM scrutiny
And so, another working week will soon draw to a close. Not a moment too…
STAT+: ‘Style over substance?’ Express Scripts launches new pricing plan amid rising scrutiny of PBMs
Amid increasing scrutiny of pharmacy benefit managers, Express Scripts is launching a new pricing plan…
STAT+: Medicare advisers endorse reforms to lower drug spending
In the latest move to address prescription drug pricing, the Medicare Payment Advisory Commission unanimously…
STAT+: Pharmalittle: Appeals court allows access to abortion pill, but with restrictions; FDA official intervened on behalf of Sarepta gene therapy
Top of the morning to you. And a steamy one, it is. In fact, there…
STAT+: Sickle cell gene therapies could be cost-effective even if priced as high as $1.9 million
As the U.S. health care system prepares for expensive gene therapies, a preliminary analysis suggests…
STAT+: Pharmalittle: Where is PhRMA in the abortion pill debate? Most late-stage MS drug trials were never published
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: How many? One-third of late-stage trials testing multiple sclerosis drugs were never published
The results from more than one-third of late-stage clinical trials that tested multiple sclerosis drugs…
STAT+: Pharmalittle: Pharma execs call for reversal of abortion pill ruling; U.S. to spend $5 billion to speed Covid-19 treatments
Top of the morning to you, and a fine one it is. Clear blue skies…
6 burning questions about how the FDA will handle conflicting abortion pill decisions
A dueling pair of federal court decisions has thrown the fate of the abortion pill…
STAT+: Pharmalittle: Abortion pill ruling could threaten FDA approval authority; Lilly CEO warns EU pharma legislation will hurt innovation
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…